Trans-Cutaneous Bilirubinometery versus Serum Bilirubin

in Neonatal Jaundice by Mahram, Manoochehr et al.
 
ORIGINAL ARTICLE  
 
Corresponding Author: S. Oveisi 
Department of Community of Medicine, Metabolic Diseases Research Center, Qazvin University of Medical Sciences, Qazvin, Iran 
Tel: +98 912 5042401, Fax: +98 281 3326033, E-mail address: soveisi@razi.tums.ac.ir 
  
Trans-Cutaneous Bilirubinometery versus Serum Bilirubin  
in Neonatal Jaundice 
Manoochehr Mahram1, Sonia Oveisi2, and Najmeh Jaberi3 
1 Department of Pediatrics, Children Growth Research Center, Qazvin University of Medical Science, Qazvin, Iran 
2 Department of Community of Medicine, Metabolic Diseases Research Center,  
Qazvin University of Medical Sciences, Qazvin, Iran 
3 School of Medicine, Qazvin University of Medical Science, Qazvin, Iran 
 
Received: 22 Jan. 2014; Accepted: 23 Oct. 2014 
 
Abstract- Hyperbilirubinemia is a common problem in neonates and causes serious complications. Thus, 
serial measurements of bilirubin should be done. This assessment is done through two methods of laboratory 
measurement in serum sample and transcutaneous bilirubinometer. This descriptive study compared 
transcutaneous bilirubin assessment and laboratory serum bilirubin. Bilirubin level was assessed among 256 
neonates admitted to the Qods Children’s Hospital in Qazvin- Iran, because of neonatal indirect jaundice, 
through two methods of transcutaneous bilirubinometery from two sites of forehead and sternum and 
laboratory measurement of bilirubin in serum. The cases were non-hemolytic icteric term neonates weighing 
2500 gram or more and had not received phototherapy or other treatments. Neonates with hemolytic forms of 
jaundice, sepsis and suspicious to metabolic disorders were excluded. Assessments by means of KJ-8000 
transcutaneous bilirubinometer from two sites of forehead and sternum and through laboratory measurement 
of serum bilirubin were registered and analyzed. The results of the current study showed that there was a 
correlation of 0.82 between serum bilirubin and transcutaneous forehead bilirubin assessment and for the used 
device sensitivity of 0.844; specificity of 0.842, Youden Index of 0.709 and Shortest of 0.042 for a cut-off of 
12.4 in bilirubin of participants. Furthermore, Likelihood Ratio positive and negative (LR) were 5.665 and 
0.164, respectively and diagnostic Odds Ratio (LR+/LR-) was 34.56. Transcutaneous bilirubinometery can be 
considered as a reliable tool to assess bilirubin for the screening of neonatal jaundice in term neonates.  
© 2015 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran 2015;53(12):764-769.  
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Introduction 
 
Hyperbilirubinemia is a common and in most cases 
benign problem in neonates. Jaundice is observed 
during the first week of life in approximately 60 
percent of term infants and 80 percent of preterm 
infants. Hyperbilirubinemia itself does not have any 
harm for the body unless exceeds a level which leads 
to kernicterus, or bilirubin encephalopathy, that is a 
neurologic syndrome resulting from the deposition of 
unconjugated (indirect) bilirubin in the basal ganglia 
and brainstem nuclei. Reliable estimates of the 
frequency of the clinical syndrome are not available 
because of the wide spectrum of manifestations. Overt 
neurologic signs have a grave prognosis; more than 
75% of infants die, and 80% of affected survivors have 
bilateral choreoathetosis with involuntary muscle 
spasms. Mental retardation, deafness, and spastic 
quadriplegia are common. The precise blood level 
above which indirect-reacting bilirubin or free bilirubin 
will be toxic for an individual infant is unpredictable 
and the duration of exposure to high bilirubin levels 
needed to produce toxic effects is unknown (1). 
To prevent this complication and to do appropriate 
management such as blood exchange or phototherapy as 
soon as possible, all susceptible neonates with jaundice 
are checked for serum level of bilirubin. Once this 
check-up is merely as a screening test and in some cases 
with near-critical levels, serial measurements should be 
done. Besides the traditional method of measurement of 
Total Serum Bilirubin (TSB) level, today, non-invasive 
techniques for Transcutaneous Measurement of 
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Bilirubin (TCB) are used. This is recommended to use 
TCB just to screen infants, and determination of serum 
bilirubin level is indicated in patients with elevated age-
specific transcutaneous bilirubin measurement, 
progressing jaundice, or risk for either hemolysis or 
sepsis (1,2). 
Blood sampling for measurement of TSB is a painful 
procedure, may increase the risk of infection and scar 
formation, may lead to anemia in the cases of frequent 
sampling especially in premature newborns and also 
causes discomfort to infants and anxiety in parents (3,4). 
On the other hand, TCB is a safe and rapid method to 
assess the level of bilirubin.   
This descriptive study was carried out to compare 
transcutaneous bilirubin assessment from two sites of 
forehead and sternum to laboratory measurement of 
bilirubin in serum. 
  
Materials and Methods 
 
A total of 256 neonates admitted to the Qods 
Children’s Hospital in Qazvin- Iran, because of neonatal 
indirect jaundice and for receiving phototherapy were 
studied from March to September 2012. The sample size 
was calculated by the below-mentioned formula, 
considering P=0.08 and d=0.05: 
 
 
n ൌ
pሺ1 െ pሻሺzଵି஑ଶሻ
ଶ
dଶ  
 
 
All parents of the children provided written 
informed consent before enrollment and results were 
confidential. The ethics review board of the Qazvin 
University of Medical Sciences approved the study. 
Bilirubin was evaluated using two methods: The first, 
serum bilirubin was measured by laboratory, and then 
bilirubin was assessed by transcutaneous 
bilirubinometer in two sites (forehead and sternum). 
The used device was KJ-8000 Transcutaneous Jaundice 
Meter, made by Xuzhou Kejian High-Tech Co., Ltd. 
with a registered product standard number of 
YZB/SU0372/2007.  
The used device has an accuracy of ≤6 percent 
preset value and continuous variable of ≤3 percent. 
Choosing forehead and sternum for transcutaneous 
bilirubin assessment was with regard to some previous 
studies in which the best correlation with TSB had 
been shown (5-6).  
The other background data used for this study 
included body weight, sex, and gestational age. Body 
weight was measured by means of a balanced beam 
scale while wearing only a baby’s nappy.   
Excluding low birth-weight and/or preterm 
neonates, neonates with hemolytic forms of jaundice, 
sepsis and suspicious to metabolic disorders; the cases 
were selected among non-hemolytic term neonates 
weighing 2500 gram or more, hospitalized to receive 
phototherapy. All included neonates in the study had 
not been under phototherapy, or other types of 
treatment before hospitalization and also all 
assessments of TCB and TSB were done at the 
beginning of entry and before receiving phototherapy 
in our hospital.  
Excel office 2007 and SPSS version 19 were used 
for descriptive analyzes. Differences between serum 
bilirubin and transcutaneous one were tested using 
Pearson correlations in two stages: (a) in all cases (b) 
in neonates with bilirubin more than 15. The Receiver 
Operating Characteristic (ROC) curve was used to the 
classifying beginning of phototherapy in non-
hemolytic icteric term neonates with 2500 gram and 
more. ROC has correctly discriminated subjects 
developing end points from the others without end 
points (0.5 and 1.0 are chance and perfect 
discrimination respectively). Sensitivity and specificity 
were measured to present the probability of truly 
identifying diseased and non-diseased individuals, 
respectively. In addition, the Youden Index as the 
maximum potential effectiveness of transcutaneous test 
(sensitivity +specificity -1) and the point of shortest 
distance value (1-sensitivity) 2 + (1-specificity) 2 were 
measured. These methods were used to diagnose the 
optimal bilirubin cut-off in neonatal jaundice as 
predispose to begin phototherapy (7,8).  
Furthermore, to assess the value of performing 
transcutaneous bilirubinometer as a diagnostic test for 
treatment, the Likelihood Ratio Positive (LR+) and 
Likelihood Ratio Negative (LR–) were assessed.  
 
Results 
 
A total of 256 neonates, including 129(50.4%) girls 
and 127(49.6%) boys, with average gestational age, 
ranged between 37 to 41 weeks (39.58 ± 0.83) consisted 
the samples. Data of bilirubin in serum and 
transcutaneous assessment in forehead and sternum are 
shown in Table 1.  
Furthermore, we have interested to evaluate the 
correlation between serum bilirubin and transcutaneous 
bilirubin in neonates in Tables (2,3). (Table 2: in 256 
Trans-cutaneous bilirubinometery vs. serum bilirubin 
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neonates and Table 3: in 123 neonates with serum 
bilirubin more than 15). Results indicated that ρ Pearson  
is decreasing from 0.82 to 0.55 when serum bilirubin is 
rising in neonates. 
 
 
 
Table 1. Mean and SD of bilirubin in serum and transcutaneous 
bilirubin in forehead and sternum 
 Min. Max. Mean 75th percentile SD 
TCB-forehead 2.00 24.80 12.62 16.40 4.69 
TCB-sternum 3.50 24.00 11.99 17.30 5.31 
Serum Bilirubin 6.10 27.00 15.02 19.20 4.89 
*TCB=Transcutaneous Measurement of Bilirubin
 
 
 
Table 2. Comparing the results of TCB from forehead and sternum 
and TSB in 256 neonates 
 TCB-
forehead
TCB-
sternum
Serum 
Bilirubin 
TCB-forehead Pearson Correlation 1   Sig. (2-tailed)    
TCB-sternum Pearson Correlation .923
* 1  
Sig. (2-tailed) .001   
Serum 
Bilirubin 
Pearson Correlation .820* .830* 1 
Sig. (2-tailed) .001 .001  
N 256 256  
*Correlation is significant at the 0.01 level (2-tailed). TCB=Transcutaneous Measurement 
of Bilirubin 
 
 
Table 3. Comparing the results of TCB from forehead and sternum and TSB 
in 123 neonates with TSB>15 mg/dL 
 TCB-
forehead 
TCB-
sternum 
Serum 
Bilirubin 
TCB-forehead Pearson Correlation 1   
Sig. (2-tailed)    
TCB-sternum Pearson Correlation .883* 1  
Sig. (2-tailed) .001   
Serum Bilirubin Pearson Correlation .549* .583* 1 
Sig. (2-tailed) .001 .001  
N 123 123 123 
*Correlation is significant at the 0.01 level (2-tailed). TCB=Transcutaneous Measurement of Bilirubin 
 
 
Figure 1. Sensitivity and specificity for trans-coetaneous bilirubin test by ROC analysis 
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Figure 2. Youden Index and Shortest for cut-off 12.4 in bilirubin of patients with neonate jaundice 
 
Moreover, for the used device in this study regarding 
bilirubin assessment through the forehead, ROC analysis 
showed the sensitivity of 0.844 and specificity of 0.842 
(Figure 1), Youden Index of 0.709 and Shortest of 0.042 
for cut-off 12.4 in serum bilirubin in neonatal jaundice 
(Figure 2). On the other hand, LR+ and LR-were 5.665 
and 0.164, respectively. Diagnostic Odds Ratio 
(LR+/LR-) was 34.56.  
 
Discussion 
 
Regarding the results of the current study, TCB 
underestimated measures comparing to TSB. For the 
used device of percutaneous bilirubinometery from the 
forehead, there is a sensitivity of 0.844; specificity of 
0.842, Youden Index of 0.709 and Shortest of 0.042 for 
a cut-off of 12.4 in bilirubin of patients with neonatal 
jaundice. Furthermore, LR+ and LR- were 5.665 and 
0.164, respectively and diagnostic Odds Ratio (LR+/LR-
) was 34.56.  
The Youden index (J), a function of sensitivity (q) 
and specificity (p), is a commonly used measure of 
overall diagnostic effectiveness. This index ranges 
between 0 and 1, with values close to 1 indicating that 
the biomarker’s effectiveness is relatively large and 
values close to 0 indicating limited effectiveness (10) 
and for evaluation, the values of 0.55, 0.65, 0.75, and 
0.85 indicate that the diagnostic accuracy of the test is at 
the acceptable, good, very good, or excellent levels, 
respectively (10).  
Therefore, this index as 0.709 indicates the good 
accuracy of the device. On the other hand, likelihood 
ratio, a measure derived from the sensitivity and 
specificity of a test is defined as the ratio between the 
probability of observing that result in patients with the 
disease in question, and the probability of that result in 
patients without the disease. LR+ is defined as the 
probability of an individual with disease having a 
positive test divided by the probability of an individual 
without disease having a positive test and LR− is 
defined as the probability of an individual with disease 
having a negative test divided by the probability of an 
individual without disease having a negative test (11). 
LR of greater than 1 indicates the test result is associated 
with the disease and LR less than 1 indicates that the 
result is associated with the absence of the disease. 
Tests, where the LR lie close to 1, have little practical 
significance as the post-test probability (odds) is little 
different from the pre-test probability, and as such is 
used primarily for diagnostic purposes, and not 
screening purposes. When the positive likelihood ratio is 
greater than 5 or the negative likelihood ratio is less than 
0.2 (i.e. 1/5) then they can be applied to the pre-test 
probability of a patient having the disease tested for to 
estimate a post-test probability of the disease state 
existing (12). This shows that the LR+ and LR- 
measures of the current study, i.e., 5.665 and 0.164, 
respectively were acceptable. 
Rodríguez-Capote et al., assessed the association 
between TCB measurements, performed using Bili-
Check or Minolta Air-Shields JM-103, and TSB and 
evaluated the predictive accuracy of TCB measurements 
for risk using the nomogram. They found that both 
devices had a good correlation with the laboratory 
method, but underestimated the serum bilirubin. In that 
study, after correcting for the differences using either the 
bias or the 95% CI the false negative rate was reduced to 
zero in all cases. They concluded that TCB 
measurements cannot be directly applied to a TSB 
nomogram but must be adjusted for any observed biases 
to avoid misclassifying newborns at risk for 
hyperbilirubinemia (13).  Similarly, Wainer et al., and 
Sajjadian et al., found the same underestimation in their 
study (14,15). Although these studies were in agreement 
with ours, in the study carried out by Panburana et al., 
Trans-cutaneous bilirubinometery vs. serum bilirubin 
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they found higher levels of bilirubin through TCB than 
TSB. The result of their study revealed that TCB and 
TSB values had a linear correlation with a significant 
correlation coefficient (r 0.81, P<0.001). The correlation 
equation was TSB=0.88 + 0.89 x TCB (r2=0.65). TCB 
levels tended be higher than TSB with mean difference 
of 0.44 mg/dL (95% CI: 0.7433-0.1323 mg/dL) and 
SD:1.64. TSB confirmation was recommended when 
TCB cut-off values greater than 9, 12, 13, 15 mg/dL at 
24 (TSB:8 mg/dL), 36 (TSB: 10 mg/dL), 48 (TSB: 12 
mg/dL) and 72 (TSB: 15 mg/dL) hours' postnatal age, 
respectively. They concluded that the TCB levels can 
accurately predict TSB with the different cut-off points 
at various postnatal ages before phototherapy (16). The 
results of the study by Imani et al., despite showing 
TCB measures higher than TSB indicated a high 
correlation between two methods of measurement.  
As above-mentioned studies showed, some 
difference could be seen in values of TCB comparing 
TSB that TCB in some studies was higher and in some 
others was lower than TSB. The reason may be due to 
some factors such as difference in devices of 
transcutaneous bilirubinometery, difference in skin 
darkness of cases, probably including cases with 
haemolytic jaundice in some studies (showing TSB 
levels higher than TCB because the rate of bilirubin 
production in serum is higher and earlier than the time 
skin becomes icteric), probably including some cases 
who had received phototherapy before assessments, and 
so on (17).  
Although some studies have shown the correlation 
between two methods of TCB and TSB assessment, 
even in preterm neonates and those with low/very low 
birth weight (19-21), some other accept it as a reliable 
tool just for the term and late preterm neonates (22,23). 
Nearly all studies accept TCB as a good device for 
screening of hyperbilirubinemia, especially in term 
neonates and non-hemolytic jaundice.  Transcutaneous 
bilirubinometery with having a good diagnostic 
accuracy can be considered as a reliable tool to assess 
bilirubin for the screening of neonatal jaundice to reduce 
repeated blood sampling. This method is more reliable 
when is used in term neonates and those with lower 
levels than blood exchange levels. 
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